{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:09:44Z","timestamp":1792501784579,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["11564, 13535"],"award-info":[{"award-number":["11564, 13535"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"DOI":"10.1007\/s00018-025-05727-4","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T02:19:21Z","timestamp":1748225961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Good manufacturing practice production of an off-the-shelf CD34+ progenitor-derived NK cell product with preserved anti-tumor functionality post-infusion in NOD\/SCID\/IL2Rgnull mice"],"prefix":"10.1007","volume":"82","author":[{"given":"Laura","family":"Hooijmaijers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Vidal-Manrique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Spils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diede","family":"van Ens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica Casta\u00f1o","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemijn","family":"Hobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"de Goede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"van Dorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop H.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anniek B.","family":"van der Waart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K. J. D.","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3998-687X","authenticated-orcid":false,"given":"Harry","family":"Dolstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"5727_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/sj.emboj.7600019","volume":"232","author":"L Moretta","year":"2004","unstructured":"Moretta L, Moretta A (2004) Unravelling natural killer cell function: triggering and inhibitory human NK receptors. Embo J 232:255\u2013259. https:\/\/doi.org\/10.1038\/sj.emboj.7600019","journal-title":"Embo J"},{"key":"5727_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"95","author":"E Vivier","year":"2008","unstructured":"Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 95:503\u2013510. https:\/\/doi.org\/10.1038\/ni1582","journal-title":"Nat Immunol"},{"key":"5727_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","volume":"151","author":"N Lamers-Kok","year":"2022","unstructured":"Lamers-Kok N, Panella D, Georgoudaki AM, Liu H, \u00d6zkazanc D, Ku\u010derov\u00e1 L et al (2022) Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. J Hematol Oncol 151:164. https:\/\/doi.org\/10.1186\/s13045-022-01382-5","journal-title":"J Hematol Oncol"},{"key":"5727_CR4","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.2022016200","volume":"1418","author":"MM Berrien-Elliott","year":"2023","unstructured":"Berrien-Elliott MM, Jacobs MT, Fehniger TA (2023) Allogeneic natural killer cell therapy. Blood 1418:856\u2013868. https:\/\/doi.org\/10.1182\/blood.2022016200","journal-title":"Blood"},{"key":"5727_CR5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1537-2995.2006.01145.x","volume":"473","author":"DH McKenna Jr","year":"2007","unstructured":"McKenna DH Jr., Sumstad D, Bostrom N, Kadidlo DM, Fautsch S, McNearney S et al (2007) Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion 473:520\u2013528. https:\/\/doi.org\/10.1111\/j.1537-2995.2006.01145.x","journal-title":"Transfusion"},{"key":"5727_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3109\/14653249.2010.515582","volume":"131","author":"MA Geller","year":"2011","unstructured":"Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA et al (2011) A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 131:98\u2013107. https:\/\/doi.org\/10.3109\/14653249.2010.515582","journal-title":"Cytotherapy"},{"key":"5727_CR7","doi-asserted-by":"publisher","first-page":"e1017701","DOI":"10.1080\/2162402x.2015.1017701","volume":"47","author":"J Cany","year":"2015","unstructured":"Cany J, van der Waart AB, Spanholtz J, Tordoir M, Jansen JH, van der Voort R et al (2015) Combined IL-15 and IL-12 drives the generation of CD34(+)-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer. Oncoimmunology 47:e1017701. https:\/\/doi.org\/10.1080\/2162402x.2015.1017701","journal-title":"Oncoimmunology"},{"key":"5727_CR8","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1007\/s00262-023-03492-6","volume":"7210","author":"P de Jonge","year":"2023","unstructured":"de Jonge P, van Hauten PMM, Janssen LD, de Goede AL, Berrien-Elliott MM, van der Meer JMR et al (2023) Good manufacturing practice production of CD34(+) progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia. Cancer Immunol Immunother 7210:3323\u20133335. https:\/\/doi.org\/10.1007\/s00262-023-03492-6","journal-title":"Cancer Immunol Immunother"},{"key":"5727_CR9","doi-asserted-by":"publisher","first-page":"e1320630","DOI":"10.1080\/2162402x.2017.1320630","volume":"68","author":"JS Hoogstad-van Evert","year":"2017","unstructured":"Hoogstad-van Evert JS, Cany J, van den Brand D, Oudenampsen M, Brock R, Torensma R et al (2017) Umbilical cord blood CD34(+) progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD\/SCID\/IL2Rg(null) mice. Oncoimmunology 68:e1320630. https:\/\/doi.org\/10.1080\/2162402x.2017.1320630","journal-title":"Oncoimmunology"},{"key":"5727_CR10","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00262-020-02749-8","volume":"705","author":"JMR Van der Meer","year":"2021","unstructured":"Van der Meer JMR, Maas RJA, Guldevall K, Klarenaar K, de Jonge P, Evert JSH et al (2021) IL-15 superagonist N-803 improves IFN\u03b3 production and killing of leukemia and ovarian cancer cells by CD34(+) progenitor-derived NK cells. Cancer Immunol Immunother 705:1305\u20131321. https:\/\/doi.org\/10.1007\/s00262-020-02749-8","journal-title":"Cancer Immunol Immunother"},{"key":"5727_CR11","doi-asserted-by":"publisher","first-page":"e14290","DOI":"10.1097\/md.0000000000014290","volume":"985","author":"J Hoogstad-van Evert","year":"2019","unstructured":"Hoogstad-van Evert J, Bekkers R, Ottevanger N, Schaap N, Hobo W, Jansen JH et al (2019) Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study). Med (Baltim) 985:e14290. https:\/\/doi.org\/10.1097\/md.0000000000014290","journal-title":"Med (Baltim)"},{"key":"5727_CR12","doi-asserted-by":"publisher","first-page":"1304689","DOI":"10.3389\/fimmu.2023.1304689","volume":"14","author":"JN Saultz","year":"2023","unstructured":"Saultz JN, Otegbeye F (2023) Optimizing the cryopreservation and post-thaw recovery of natural killer cells is critical for the success of off-the-shelf platforms. Front Immunol 14:1304689. https:\/\/doi.org\/10.3389\/fimmu.2023.1304689","journal-title":"Front Immunol"},{"key":"5727_CR13","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1038\/s41467-024-47574-0","volume":"151","author":"A Berjis","year":"2024","unstructured":"Berjis A, Muthumani D, Aguilar OA, Pomp O, Johnson O, Finck AV et al (2024) Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation. Nat Commun 151:3937. https:\/\/doi.org\/10.1038\/s41467-024-47574-0","journal-title":"Nat Commun"},{"key":"5727_CR14","doi-asserted-by":"publisher","first-page":"5224","DOI":"10.1038\/s41467-020-19094-0","volume":"111","author":"C Mark","year":"2020","unstructured":"Mark C, Czerwinski T, Roessner S, Mainka A, H\u00f6rsch F, Heublein L et al (2020) Cryopreservation impairs 3-D migration and cytotoxicity of natural killer cells. Nat Commun 111:5224. https:\/\/doi.org\/10.1038\/s41467-020-19094-0","journal-title":"Nat Commun"},{"key":"5727_CR15","doi-asserted-by":"publisher","first-page":"861681","DOI":"10.3389\/fimmu.2022.861681","volume":"13","author":"JL Oyer","year":"2022","unstructured":"Oyer JL, Croom-Perez TJ, Dieffenthaller TA, Robles-Carillo LD, Gitto SB, Altomare DA et al (2022) Cryopreserved PM21-particle-expanded natural killer cells maintain cytotoxicity and effector functions in vitro and in vivo. Front Immunol 13:861681. https:\/\/doi.org\/10.3389\/fimmu.2022.861681","journal-title":"Front Immunol"},{"key":"5727_CR16","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jcyt.2016.02.008","volume":"186","author":"A Domogala","year":"2016","unstructured":"Domogala A, Madrigal JA, Saudemont A (2016) Cryopreservation has no effect on function of natural killer cells differentiated in vitro from umbilical cord blood CD34(+) cells. Cytotherapy 186:754\u2013759. https:\/\/doi.org\/10.1016\/j.jcyt.2016.02.008","journal-title":"Cytotherapy"},{"key":"5727_CR17","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3109\/14653249.2012.700767","volume":"149","author":"N Lapteva","year":"2012","unstructured":"Lapteva N, Durett AG, Sun J, Rollins LA, Huye LL, Fang J et al (2012) Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy 149:1131\u20131143. https:\/\/doi.org\/10.3109\/14653249.2012.700767","journal-title":"Cytotherapy"},{"key":"5727_CR18","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.bbmt.2014.05.004","volume":"208","author":"JS Miller","year":"2014","unstructured":"Miller JS, Rooney CM, Curtsinger J, McElmurry R, McCullar V, Verneris MR et al (2014) Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transpl 208:1252\u20131257. https:\/\/doi.org\/10.1016\/j.bbmt.2014.05.004","journal-title":"Biol Blood Marrow Transpl"},{"key":"5727_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0022-1759(93)90102-d","volume":"1651","author":"H Voshol","year":"1993","unstructured":"Voshol H, Dullens HF, Den Otter W, Vliegenthart JF (1993) Human natural killer cells: a convenient purification procedure and the influence of cryopreservation on cytotoxic activity. J Immunol Methods 1651:21\u201330. https:\/\/doi.org\/10.1016\/0022-1759(93)90102-d","journal-title":"J Immunol Methods"},{"key":"5727_CR20","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jcyt.2019.07.004","volume":"219","author":"R Li","year":"2019","unstructured":"Li R, Johnson R, Yu G, McKenna DH, Hubel A (2019) Preservation of cell-based immunotherapies for clinical trials. Cytotherapy 219:943\u2013957. https:\/\/doi.org\/10.1016\/j.jcyt.2019.07.004","journal-title":"Cytotherapy"},{"key":"5727_CR21","doi-asserted-by":"publisher","first-page":"250e1","DOI":"10.1016\/j.jtct.2022.02.008","volume":"285","author":"F Otegbeye","year":"2022","unstructured":"Otegbeye F, Cooper B, Caimi P, Zamborsky K, Reese-Koc J, Hillian A et al (2022) A phase I study to determine the maximum tolerated dose of ex vivo expanded natural killer cells derived from unrelated, HLA-disparate adult donors. Transpl Cell Ther 285:250e1\u2013e8. https:\/\/doi.org\/10.1016\/j.jtct.2022.02.008","journal-title":"Transpl Cell Ther"},{"key":"5727_CR22","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/s41592-022-01507-1","volume":"197","author":"D Ershov","year":"2022","unstructured":"Ershov D, Phan MS, Pylv\u00e4n\u00e4inen JW, Rigaud SU, Le Blanc L, Charles-Orszag A et al (2022) TrackMate 7: integrating state-of-the-art segmentation algorithms into tracking pipelines. Nat Methods 197:829\u2013832. https:\/\/doi.org\/10.1038\/s41592-022-01507-1","journal-title":"Nat Methods"},{"key":"5727_CR23","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"97","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 97:676\u2013682. https:\/\/doi.org\/10.1038\/nmeth.2019","journal-title":"Nat Methods"},{"key":"5727_CR24","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/j.1537-2995.2007.01212.x","volume":"475","author":"HT Meryman","year":"2007","unstructured":"Meryman HT (2007) Cryopreservation of living cells: principles and practice. Transfusion 475:935\u2013945. https:\/\/doi.org\/10.1111\/j.1537-2995.2007.01212.x","journal-title":"Transfusion"},{"key":"5727_CR25","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","volume":"292","author":"V Ort\u00edz-Maldonado","year":"2021","unstructured":"Ort\u00edz-Maldonado V, Rives S, Castell\u00e0 M, Alonso-Saladrigues A, Ben\u00edtez-Ribas D, Caballero-Ba\u00f1os M et al (2021) CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19(+) relapsed\/refractory malignancies. Mol Ther 292:636\u2013644. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.027","journal-title":"Mol Ther"},{"key":"5727_CR26","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1080\/10428194.2018.1455975","volume":"5912","author":"R Reich-Slotky","year":"2018","unstructured":"Reich-Slotky R, Makhani SS, Vasovic LV, Pearse RN, Rossi A, Philips A et al (2018) Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products. Leuk Lymphoma 5912:2829\u20132835. https:\/\/doi.org\/10.1080\/10428194.2018.1455975","journal-title":"Leuk Lymphoma"},{"key":"5727_CR27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/cji.0000000000000059","volume":"381","author":"S Szmania","year":"2015","unstructured":"Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B et al (2015) Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother 381:24\u201336. https:\/\/doi.org\/10.1097\/cji.0000000000000059","journal-title":"J Immunother"},{"key":"5727_CR28","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jcyt.2020.05.001","volume":"228","author":"SN Damodharan","year":"2020","unstructured":"Damodharan SN, Walker KL, Forsberg MH, McDowell KA, Bouchlaka MN, Drier DA et al (2020) Analysis of ex vivo expanded and activated clinical-grade human NK cells after cryopreservation. Cytotherapy 228:450\u2013457. https:\/\/doi.org\/10.1016\/j.jcyt.2020.05.001","journal-title":"Cytotherapy"},{"key":"5727_CR29","doi-asserted-by":"publisher","first-page":"e64384","DOI":"10.1371\/journal.pone.0064384","volume":"86","author":"J Cany","year":"2013","unstructured":"Cany J, van der Waart AB, Tordoir M, Franssen GM, Hangalapura BN, de Vries J et al (2013) Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD\/SCID\/IL2Rg(null) mice. PLoS ONE 86:e64384. https:\/\/doi.org\/10.1371\/journal.pone.0064384","journal-title":"PLoS ONE"},{"key":"5727_CR30","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jcyt.2023.11.009","volume":"263","author":"PMM van Hauten","year":"2024","unstructured":"van Hauten PMM, Hooijmaijers L, Vidal-Manrique M, van der Waart AB, Hobo W, Wu J et al (2024) Engineering of CD34\u2009+\u2009progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity. Cytotherapy 263:252\u2013260. https:\/\/doi.org\/10.1016\/j.jcyt.2023.11.009","journal-title":"Cytotherapy"},{"key":"5727_CR31","doi-asserted-by":"publisher","unstructured":"Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D et al (2013) NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). https:\/\/doi.org\/10.1182\/blood-2012-04-425397. Blood 12118:3599\u2013608","DOI":"10.1182\/blood-2012-04-425397"},{"key":"5727_CR32","doi-asserted-by":"publisher","first-page":"1981049","DOI":"10.1080\/2162402x.2021.1981049","volume":"101","author":"JMR Van der Meer","year":"2021","unstructured":"Van der Meer JMR, de Jonge P, van der Waart AB, Geerlings AC, Moonen JP, Brummelman J et al (2021) CD34(+) progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD\/SCID\/IL2Rg(null) mice. Oncoimmunology 101:1981049. https:\/\/doi.org\/10.1080\/2162402x.2021.1981049","journal-title":"Oncoimmunology"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05727-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-025-05727-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05727-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T02:19:21Z","timestamp":1748225961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-025-05727-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5727"],"URL":"https:\/\/doi.org\/10.1007\/s00018-025-05727-4","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"UCB was collected following written informed consent from delivery at the Radboudumc (CMO 2014\u2009\u2212\u2009226) or from the Radboudumc cord blood bank. Ethical approval for animal studies was granted by the Dutch central committee of animal experiments (DEC 2018-0029).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare that they have no financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}